phase II trial weekli biweekli intraperiton mitoxantron epitheli ovarian cancer previou experiment clinic evalu ovarian cancer sensit cytotox effect mitoxantron concentr achiev periton caviti intraperiton IP administr use drug IP high dose normal salin NS monthli schedul sever local effect secondari irrit properti drug toxic advantag minim system drug exposur IP administr patient drug concentr mitoxantron NS weekli week schedul total cours monthli program regimen pain cumul dose mitoxantron seriou treatment-rel morbid assess patient tumor equal cm diamet respons patient minim respons improv toxic profil regimen overal respons rate similar monthli program secondari IP drug distribut mani patient futur investig effort IP mitoxantron therapi ovarian cancer method drug deliveri site tumor periton caviti eg intraop therapi treatment volum antiinflammatori agent adhes format 